HIGHLIGHTS
- who: Moudi M. Alasmari from the College of Medicine, King Saud Bin Abdul Aziz University for Health Sciences (KSAU-HS), King Abdullah International Medical Research Centre (KAIMRC), Jeddah, Saudi Arabia have published the research work: A Review of Margetuximab-Based Therapies in Patients with HER2-Positive Metastatic Breast Cancer, in the Journal: Cancers 2023, 38 of 13/Dec/2022
- what: ErbB2 receptors are capable of enhancing the malignancy of solid tumors, including breast and gastric cancers, and sustaining cancer types resistant to conventional therapies.
- how: A phase 1 trial (NCT01148849) was developed to . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.